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LETTER TO THE EDITOR Open Access
Response to the Letter to the Editor by
Eberhard et al.
Christian Bottomley1*, Valerie Isham2, Sarai Vivas-Martínez3, Annette C. Kuesel4, Simon K. Attah5,
Nicholas O. Opoku6, Sara Lustigman7, Martin Walker8,9† and Maria-Gloria Basáñez8†
Abstract
In a Letter to the Editor, Eberhard et al. question the validity of our model of skin snip sensitivity and argue against
the use of skin snips to evaluate onchocerciasis elimination by mass drug administration. Here we discuss their
arguments and compare model predictions with observed data to assess the validity of our model.
Letter to the Editor
In our recent paper in Parasites & Vectors [1], we pre-
sented a model of the number of microfilariae (mf) per
skin snip, which we used to predict the sensitivity of skin
snips as a test for detecting patent Onchocerca volvulus
infection when a treatment programme, based on mass
drug administration (MDA) with ivermectin, is close to
achieving elimination. We concluded that our model
supports the recommendation of the African Programme
for Onchocerciasis Control (APOC) to conduct skin snip
surveys 3–5 years post-MDA, and that sensitivity
could be improved by taking four skin snips rather
than two. Based on the findings from our model, we
argued that skin snips are useful, when used together
with entomological and serological data, for evaluating
programmes of MDA.
In a Letter to the Editor, Eberhard and colleagues [2]
suggest that our model of skin snip sensitivity is misspe-
cified, and argue that skin snips should not be used for
evaluating onchocerciasis elimination by mass drug ad-
ministration because they have poor sensitivity and indi-
viduals are often reluctant to be skin-snipped.
Eberhard et al. begin their critique by suggesting our
model is misspecified. In particular, they question our
assumption that the number of mf per skin snip follows
a negative binomial distribution (conditional on adult fe-
male worm burden) and suggest that a zero-inflated dis-
tribution might be more appropriate. As we discussed in
our paper, there are good theoretical reasons for choos-
ing this model, and it fits the data well. Specifically, it
does not underestimate the proportion of skin snips with
zero mf (Fig. 1), as the authors suggest it might. We be-
lieve a zero-inflated model is therefore unnecessary.
The authors then present two arguments against the
use of skin snips for evaluating programmes of MDA.
Their first argument is that skin snip sensitivity is known
to be low. But they present an estimate of sensitivity
(20%) without reference to either time after treatment or
number of skin snips. By itself, this figure is uninforma-
tive since, as we have shown, sensitivity ranges from zero
to c.100%, depending on the number of skin snips taken
and when they are taken after treatment. For two skin
snips, our model predicts low sensitivity (≤ 31%) one
year after treatment, which is consistent with data pre-
sented by Thiele et al. [3].
Their second argument is that skin snips are not useful
because people are sometimes reluctant to be skin-
snipped; they cite as evidence the low rates of participa-
tion in the Mali/Senegal study [4, 5] (c.70% participated in
the first survey conducted after the last round of MDA
and c.50% in the fourth skin snip survey 3–4 years later).
We acknowledged this limitation in our paper when we
said that, “communities are increasingly reluctant to par-
ticipate in skin snipping, so a compromise must be found
between what is feasible and the ideal” and that “strategies
and surveillance should be implemented using tests that
are less invasive than the skin snip method.” Nonetheless,
we believe skin snip data from the Mali/Senegal study are
useful since they were used successfully to model the like-
lihood of elimination and recrudescence [6], and the
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model predictions are now supported by Ov16 serological
data from Senegal indicating that elimination may not
have been sustained in the River Gambia focus [7].
Eberhard et al. conclude that “country program man-
agers must be made aware of the extreme lack of
usefulness of skin snips in assessing the elimination of
Onchocerca volvulus”. However, the recommendation of
the World Health Organization (WHO) that skin snip
microscopy should not be used to demonstrate interrup-
tion of transmission [8] is only a “conditional recom-
mendation, low certainty of evidence”. Equally, program
managers should be made aware of the limitations of
Ov16 serology, particularly of the current rapid diagnostic
tests. The WHO recommendation to use Ov16 serology
in < 10-year olds to confirm transmission interruption is a
“strong recommendation”, but also based on “low cer-
tainty of evidence”, and it may need to be adapted in the
future. For example, the WHO guidelines provide a single
threshold of Ov16 seropositivity (<0.1%); however, recent
modelling suggests that it may be more appropriate to use
thresholds that depend on pre-MDA endemicity [9, 10].
Clearly, more research is needed to achieve ‘high certainty
of evidence-based recommendations’. Our study con-
tributes to this endeavour.
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Fig. 1 Proportion of iliac skin snips with zero microfilariae versus
model predictions for study communities in Guatemala, Venezuela,
Cameroon and Ghana
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